MannKind (MNKD) vs Ocular Therapeutix (OCUL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MannKind (MNKD) has outperformed Ocular Therapeutix (OCUL) over the past year, losing 23.5% versus a loss of 54.5%. Over five years, OCUL leads with a -14.8% price change compared with -16.8% for MNKD. MannKind is the larger company by market cap ($1.24 billion vs $1.23 billion), about 1.0 times the size.
MannKind converts more of its revenue into profit, with a net margin of 1.7% versus -511.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNKD | OCUL |
|---|---|---|
| Share price | $3.85 | $5.57 |
| Market cap | $1.24B | $1.23B |
| 1-day change | -2.53% | -4.95% |
| YTD return | -32.10% | -54.12% |
| 1-year return | -23.46% | -54.49% |
| 5-year return | -16.85% | -14.83% |
| Forward P/E | 24.44 | — |
| EPS (TTM) | $-0.24 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $348.97M | $51.95M |
| Revenue growth (YoY) | +22.23% | -18.47% |
| Net income (latest FY) | $5.86M | $-265.94M |
| Gross margin | 92.32% | 87.35% |
| Operating margin | 11.12% | -519.75% |
| Net margin | 1.68% | -511.90% |
| 52-week high | $6.51 | $16.44 |
| 52-week low | $2.23 | $5.54 |
| Distance from 52-week high | -40.86% | -66.12% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +116.36% | +361.94% |
| Average volume | 3.96M | 3.03M |
| Shares outstanding | 321.64M | 220.02M |
| Employees | 591 | 325 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNKD has outperformed OCUL by 31.0 percentage points over the past year.
- MannKind is more profitable, keeping 1.7 cents of every revenue dollar as net income versus -511.9 cents for Ocular Therapeutix.
- MannKind grew revenue faster in its latest fiscal year (+22.23% vs -18.47%).
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
MNKD vs OCUL FAQ
Which is bigger, MannKind or Ocular Therapeutix?
MannKind (MNKD) is larger, with a market capitalization of $1.24B compared with $1.23B for Ocular Therapeutix (OCUL).
Which stock has performed better over the past year, MNKD or OCUL?
MNKD returned -23.46% over the past 12 months, compared with -54.49% for OCUL (price return, excluding dividends). Past performance does not predict future results.
Are MannKind and Ocular Therapeutix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.